Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +63.03%
#3 MetaDAO MetaDAO +28.63%
#4 Pons Pons +28.12%
#5 Rain Rain +23.09%
#6 Bedrock Bedrock +20.96%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +17.95%
#8 Ontology Gas Ontology Gas +17.34%
#9 Prom Prom +16.62%
#10 Humanity Humanity +14.86%
Coin of the day
QuantixAI QuantixAI
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA
Kedudukan dalam Saham #20135
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Harga Saham
$2.99
Modal Pasaran
$139.84M
Perubahan (1 hari)
-0.40%
Perubahan (1 tahun)
-41.27%
Negara
DE
Perdagangan Heidelberg Pharma AG (HPHA)

Kategori

Healthcare
Margin Operasi untuk Heidelberg Pharma AG (HPHA)
Margin Operasi pada 2026 TTM: 0.00%
Menurut laporan kewangan dan harga saham terkini Heidelberg Pharma AG, margin operasi semasa (TTM) ialah 0.00%. Pada akhir 2026, margin operasi syarikat ialah 0.00%.
Sejarah Margin Operasi untuk Heidelberg Pharma AG dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Ubah
Tidak cukup data untuk tarikh yang disediakan.
Margin Operasi untuk syarikat serupa atau pesaing
Syarikat Margin Operasi Perbezaan Margin Operasi Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.